While Not the First Oral GLP-1, Daily Orforglipron Pill Could Reduce Reliance on Weight Loss Injections

In April 2026, the FDA approved an oral GLP-1 drug called orforglipron, marketed as Foundayo, marking a significant step forward in obesity treatment. This pill could potentially reduce reliance on weight loss injections such as Ozempic® and Wegovy®, which are currently administered either once a day or once a week by injection.

The active ingredients in these drugs are quickly broken down by digestive enzymes, making injections the preferred delivery method. However, injections are not ideal for all patients, as daily or even weekly injections are not enjoyable for most people.

Researchers have been working to develop oral forms of GLP-1 medications, and orforglipron appears to be the most promising so far. Approved by the FDA in April 2026, orforglipron offers several advantages over existing oral and injectable GLP-1 drugs. Its dosing schedule is simpler, as it can be taken once a day with or without food, unlike oral Wegovy, which must be taken first thing in the morning on an empty stomach with a strict no-water-rules 30 minutes post-ingestion.

Orforglipron's unique molecular structure allows it to be a non-peptide small molecule, making it more resistant to the acidic environment in the intestines and easier to absorb into the bloodstream compared to peptides like other GLP-1 drugs. This structural difference also makes orforglipron simpler and less expensive to manufacture, and it can be stored and shipped without refrigeration.

These advantages extend beyond patient convenience, as Gitanjali Srivastava, a director of Clinical Obesity Medicine and co-director of the Weight Loss Center at Vanderbilt University Medical Center, explains. The drug's global availability, due to its ease of manufacture and storage, ensures that the supply can meet the disease burden rather than being rationed by insurance coverage and access to refrigeration.

Srivastava has already been using orforglipron with her patients, but notes that daily dosing could lead to seven missed doses per week, and around a third of patients experience nausea.